Page 1

ASX / MEDIA ANNOUNCEMENT RESPIRI 26 October 2021 October 2021 Quarterly Cash Flow and Quarterly Activities Report Respiri Limited ( ASX : RSH ) ( " Respiri " or the " Company " ) , an eHealth SaaS Company supporting respiratory health management , today announces the Appendix 4C quarterly cash flow and activities for the 3 month period ended 30 September 2021 . Operating Highlights During the quarter , Respiri was announced the winner of the 2021 Good Design Gold Award for product design , medical and scientific . Winning design projects were required to demonstrate that they improve quality of life and contribute to a better , safer , and more sustainable future . wheezoⓇ has been awarded lifetime access to the Good Design Tick , recognised worldwide as one of the most respected benchmarks for innovation and design worldwide . The tick signals that wheezoⓇ is produced to the highest quality , provide good value for money and will give them a great experience and can be featured on product and marketing collateral . The Company has made its intentions around building a broader respiratory portfolio very clear and to this end has leveraged its internal expertise , to build a wearable device cost - effectively and expeditiously . The project commenced in May 2021 and the Respiri team delivered a prototype in October that is now being tested with preliminary results being positive . The initial version of the device is to be used in respiratory clinical trials and there is already strong interest in the product from multinational companies . The next generation prototype set for completion in Q2 CY2022 is designed to monitor the multiple parameters of nocturnal asthma , a therapeutic area of need as determined by Key Opinion Leaders ( KOL ) ( from Australia , Canada , Europe , UK , USA and Israel ) that were consulted during the design of the wearable . Today there is nothing available for physicians to monitor these patients and exacerbations during sleep can be particularly concerning . This technology will complement wheezoⓇ which is designed for ambulatory “ daytime " monitoring . Patents have been successful submitted for the device and the brand Sorfe has been chosen . The Respiratory Specialist led wheezoⓇ Remote Asthma Management Programme ( RAMP ) continues to grow the number of patients enrolled with almost 4 months of remote patient monitoring data captured . Although more data is required , the initial health outcome trends from this initiative appear positive and this is particularly important to demonstrate to payors and employers of the health merits of the programs which will be critical not only in Australia but the USA , UK and Europe . The intention is to grow the enrolled patient pool to about 75-100 and continue to monitor the health outcomes metrics for an initial 6 months . Analysis of the data should be available for use in mid Q1 CY2022 and possible publication afterwards . The Company has continued to invest into the upgrading of the App to increase utility and patient engagement . Added to the App was the Asthma Control Test ( ACT ) which is a clinically proven tool used by physicians to determine asthma severity and control . To the knowledge of Respiri , the wheezoⓇ App is the first in the world to incorporate this into its ecosystem which provides a convenient way of clinically - accepted validation of the impact the wheezo device on helping patients manage their asthma . Although there is much more data to be collected , the initial results are very pleasing . Respiri Limited | ABN 98 009 234 173 | Level 9 , 432 St Kilda Road , Melbourne VIC 3004 | Page | 1